Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 1 - 10 of 36 results.

You searched for : June 2020 to June 2021.

DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 ...

DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer Download the PDF version of Article June 14, 2021 Tokyo, Munich...

Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell ...

Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma Download the PDF version of Article June 11, 2021...

Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanism ...

Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC Download the PDF version of Article June 04, 2021...

Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 202 ...

Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual Meeting Download the PDF version of Article May 19, 2021 Data to highlight...

Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and D ...

Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer Download the PDF version...

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the ...

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia Download the PDF version of Article May...

Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myelo ...

Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Download the PDF version of Article April 07, 2021...

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Col ...

DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer Download the PDF version of Article April 06, 2021 Munich and Basking Ridge, NJ –...

DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Sma ...

DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer Download the PDF version of Article March 29, 2021 Tokyo, Munich and Basking...

Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with ...

Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma Download the PDF version of Article February 24, 2021 Phase 2...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...